Laboratoires Servier Signs Licensing Agreement With CELLECTIS SA For Use Of Modified Cell Lines In Drug Screening
Bernard Marchand, Servier’s Head of Research, said: “This agreement formalizes a well-established research relationship with Cellectis and will accelerate the development of high-performance screening tools for innovative drug targets.”
“The licensing agreement with Servier crowns a particularly effective partnership between the two companies’ research divisions. The cells, gene insertion templates and meganuclease used by Servier are now available as a commercial kit which provides a reliable, easy-to-use method of creating cell lines specific to drug targets of interest,” commented Marc Le Bozec, Cellectis’ Chief Financial Officer and CEO of Cellectis BioResearch, the subsidiary responsible for marketing research kits.
About Servier
Servier is France’s leading independent pharmaceutical group and is chaired by its founder Dr Jacques Servier. The group is represented in 140 countries, and posted a 2008 turnover of 3,7 billion euros. 82% of Servier’s pharmaceutical products are prescribed outside France. Servier has 19 International Centers for Therapeutic Research and 25% of the company’s expenditure is invested in R&D. The group’s main research areas are cardiovascular diseases, the central nervous system & psychiatry, cancer research, diabetes & metabolism and rheumatology.
Further information is available at www.servier.fr.
About Cellectis S.A.
Cellectis S.A. (www.cellectis.com) is a world leader in genome engineering and genome surgery. For further information about Cellectis, visit our website at www.cellectis.com.
Disclaimer
This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.